文献速递乳腺癌放疗

部分或全乳放疗不良事件比较:随机试验荟萃分析中美容效果、毒性与生活质量的研究

Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials.
PubMed 文献 · Radiat Oncol · 2023-11-02

该荟萃分析纳入16项随机试验共19085例早期乳腺癌患者,比较部分乳腺照射(PBI)与全乳照射(WBI)。PBI与任何1级及以上急性毒性和2级及以上皮肤毒性发生率更低相关,晚期不良事件和美容效果总体相似,但每日两次分割的PBI方案患者自评美容效果更差。

要点

  • PBI与任何1级及以上急性毒性(OR=0.12;95%CI 0.09-0.18;p<0.001)和2级及以上皮肤毒性(OR=0.16;95%CI 0.07-0.41;p<0.001)发生率更低相关。
  • 两种治疗在晚期不良事件及医学专业人员或患者评价的任何不良美容结局方面均无显著差异。
  • 每日两次分割的PBI技术患者自评美容效果更差(n=3215;OR=2.08;95%CI 1.22-3.54;p=0.007),而每日一次最大EBRT方案(n=2071;OR=0.60;95%CI 0.45-0.79;p<0.001)和IORT(p=0.042)医学专业人员评价美容效果更好。

核心结论

  • 与WBI相比,PBI在急性毒性和乳腺特异性生活质量方面具有优势。
  • 总体而言,晚期毒性和美容效果相似。
  • 每日两次分割方案的PBI患者自评美容效果更差。

研究设计与样本

  • 系统文献综述检索2009年后发表的比较早期乳腺癌WBI与PBI的随机试验。
  • 纳入16项研究,共19085例患者。
  • 使用已发表的事件率和效应量对可获得的急性和晚期不良事件进行荟萃分析。
  • 使用EORTC QLQ-C30和QLQ-BR23问卷评估美容结局及一般和乳腺特异性生活质量。

主要发现

  • PBI与任何1级及以上急性毒性发生率更低相关(OR=0.12;95%CI 0.09-0.18;p<0.001)。
  • PBI与2级及以上皮肤毒性发生率更低相关(OR=0.16;95%CI 0.07-0.41;p<0.001)。
  • 两种治疗在晚期不良事件方面无显著差异。
  • 两种治疗在医学专业人员或患者评价的任何不良美容结局方面无显著差异。
  • 每日两次分割的PBI技术患者自评美容效果更差(n=3215;OR=2.08;95%CI 1.22-3.54;p=0.007)。

关键数值与推荐

  • PBI与任何1级及以上急性毒性:OR=0.12;95%CI 0.09-0.18;p<0.001。
  • PBI与2级及以上皮肤毒性:OR=0.16;95%CI 0.07-0.41;p<0.001。
  • 每日两次分割PBI患者自评美容效果更差:n=3215;OR=2.08;95%CI 1.22-3.54;p=0.007。
  • 每日一次最大EBRT医学专业人员评价美容效果更好:n=2071;OR=0.60;95%CI 0.45-0.79;p<0.001。
  • IORT医学专业人员评价美容效果更好:p=0.042。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE/OBJECTIVE: Adjuvant whole breast radiotherapy and systemic therapy are part of the current evidence-based treatment protocols for early breast cancer, after breast-conserving surgery. Numerous randomized trials have investigated the therapeutic effects of partial breast irradiation (PBI) compared to whole breast irradiation (WBI), limiting the treated breast tissue. These trials were designed to achieve equal control of the disease with possible reduction in adverse events, improvements in cosmesis and quality of life (QoL). In this meta-analysis, we aimed to investigate the differences between PBI and WBI in side effects and QoL. MATERIAL/METHODS: We performed a systematic literature review searching for randomized trials comparing WBI and PBI in early-stage breast cancer with publication dates after 2009. The meta-analysis was performed using the published event rates and the effect-sizes for available acute and late adverse events. Additionally, we evaluated cosmetic outcomes as well as general and breast-specific QoL using the EORTC QLQ-C30 and QLQ-BR23 questionnaires. RESULTS: Sixteen studies were identified (n = 19,085 patients). PBI was associated with a lower prevalence in any grade 1 + acute toxicity and grade 2 + skin toxicity (OR = 0.12; 95% CI 0.09-0.18; p < 0.001); (OR = 0.16; 95% CI 0.07-0.41; p < 0.001). There was neither a significant difference in late adverse events between the two treatments, nor in any unfavorable cosmetic outcomes, rated by either medical professionals or patients. PBI-technique using EBRT with twice-daily fractionation schedules resulted in worse cosmesis rated by patients (n = 3215; OR = 2.08; 95% CI 1.22-3.54; p = 0.007) compared to WBI. Maximum once-daily EBRT schedules (n = 2071; OR = 0.60; 95% CI 0.45-0.79; p < 0.001) and IORT (p = 0.042) resulted in better cosmetic results grade by medical professionals. Functional- and symptom-based QoL in the C30-scale was not different between PBI and WBI. Breast-specific QoL was superior after PBI in the subdomains of "systemic therapy side effects" as well as "breast-" and "arm symptoms". CONCLUSION: The analysis of multiple randomized trials demonstrate a superiority of PBI in acute toxicity as well breast-specific quality of life, when compared with WBI. Overall, late toxicities and cosmetic results were similar. PBI-technique with a fractionation of twice-daily schedules resulted in worse cosmesis rated by patients.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Haussmann J, Budach W, Corradini S, et al. Comparison of adverse events in partial- or whole breast radiotherapy: investigation of cosmesis, toxicities and quality of life in a meta-analysis of randomized trials. Radiat Oncol. 2023. PMID: 37919752. doi:10.1186/s13014-023-02365-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。